300 million doses of vaccine will be produced in six months, half the stock reserved for India

Mumbai, Ta. Monday, December 28, 2020

Serum Inst, the world's largest vaccine manufacturer based in Pune. Adar Punawala, CEO of Indiana (SII), said it would be able to produce 300 million doses of Covishield in the next six months alone. The vaccine, jointly developed by Oxford University in Britain and the medical company AstraZeneca, is known in India as Covishield.

Serum is responsible for its production. Punawala said that once the vaccine is approved in India, it will be able to produce 50 million doses in a matter of days. He also assured that half of whatever we would produce would be kept in stock for the Government of India. The rest of the stock will be supplied to the world.

Emergency use of the Oxford AstraZeneca vaccine in India is expected to be approved in the next few days. "We have submitted information about the vaccine to the government and the government has found it satisfactory," Punawala said. He also said that there would be a shortage of vaccines in the early months of 2021.

Because production capacity is limited, while demand is worldwide. But by July-August 2021 the situation will be normal. The government plans to vaccinate about 300 million people in the country's first priority in the first phase of the covid vaccination campaign, which is expected to run from the first week of January to the end of July.

The Serum Institute developed the first indigenous vaccine for pneumonia, 'Pneumosil'

Poonawala claims that pneumonia vaccine is cheaper than the rest of the world: Foreign vaccine is currently used in India

Pune, Dt.28

Serum Inst, the world's largest vaccine manufacturer based in Pune. The Indiana (SII) has succeeded in developing a vaccine for pneumonia in addition to the corona vaccine.

The pneumococcal vaccine is completely indigenous and was launched today by Union Health Minister Harshvardhan. The information was shared by Serum CEO Adar Punawala on Twitter. Speaking at the online launch event, Poonawala said it was the only vaccine for pneumonia made in India.

It is also the cheapest pneumonia vaccine in the world today. Dr. Harshvardhan said the vaccine was made by India, but with the help of UNICEF, we will reach out to all the needy children in the world. The vaccine protects against ten types of pneumonia virus.

The vaccine has been developed in accordance with the guidelines of the World Health Organization. At present, two vaccines manufactured by foreign company Pfizer and GlaxoSmithKline are used in India. Both of these vaccines are a bit expensive as they are foreign. The company developed the vaccine with the help of the International Health Organization Path and the Bill-Melinda Gates Foundation.

Pneumonia is a deadly disease that afflicts children all over the world. The disease is a major cause of death in children under the age of five. In India, 65,000 children die of pneumonia every year before the age of five. The vaccine was recently developed and has now been officially launched after approval in all trials.

Kovacs: Planning for global distribution of the vaccine

The World Health Organization has launched a program called Covax for global distribution-planning of vaccines. The approved vaccine under this program, its production capacity, distribution, effectiveness of the vaccine etc. will be recorded. In particular, efforts will be made to ensure that the vaccine is distributed evenly. This is because many countries are unlikely to receive the vaccine, while Canada has ordered three times its own population. The health organization will work through Kovacs to reduce such inequality.

Net-practice of vaccination in four states

Net practice of vaccination was started today in four states including Gujarat. This process called dry run will last for two days. The challenges that arise when actually vaccinated under dry run were studied. During the process, the vaccination centers investigated the issues of vaccine registration, vaccination process, treatment if reaction occurs, care to be taken while vaccinating, maintaining distance between the people coming for vaccination, vaccine preservation etc.